Skip to main content

Table 3 Cardiotoxicity events by clinical risk score

From: Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study

 

Clinical Risk Score

Low (0–3)

Moderate (4–5)

High (≥ 6)

Patients (n)

90 (70)

25 (19)

12 (9)

Cardiotoxicity [n (%)]

6 (4)

5 (4)

2 (1)

Permanent reduced EF [n (%)]

5 (4)

2 (1)

1 (0.1)